Literature DB >> 7679000

Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow.

T Leemhuis1, D Leibowitz, G Cox, R Silver, E F Srour, G Tricot, R Hoffman.   

Abstract

Chronic myeloid leukemia (CML) is a malignant disorder of the hematopoietic stem cell. It has been shown that normal stem cells coexist with malignant stem cells in the bone marrow of patients with chronic-phase CML. To characterize the primitive hematopoietic progenitor cells within CML marrow, CD34+DR- and CD34+DR+ cells were isolated using centrifugal elutriation, monoclonal antibody labeling, and flow cytometric cell sorting. Polymerase chain reaction analysis of RNA samples from these CD34+ subpopulations was used to detect the presence of the BCR/ABL translocation characteristic of CML. The CD34+DR+ subpopulation contained BCR/ABL(+) cells in 11 of 12 marrow samples studied, whereas the CD34+DR- subpopulation contained BCR/ABL(+) cells in 6 of 9 CML marrow specimens. These cell populations were assayed for hematopoietic progenitor cells, and individual hematopoietic colonies were analyzed by PCR for their BCR/ABL status. Results from six patients showed that nearly half of the myeloid colonies cloned from CD34+DR- cells were BCR/ABL(+), although the CD34+DR- subpopulation contained significantly fewer BCR/ABL(+) progenitor cells than either low-density bone marrow (LDBM) or the CD34+DR+ fraction. These CD34+ cells were also used to establish stromal cell-free long-term bone marrow cultures to assess the BCR/ABL status of hematopoietic stem cells within these CML marrow populations. After 28 days in culture, three of five cultures initiated with CD34+DR- cells produced BCR/ABL(-) cells. By contrast, only one of eight cultures initiated with CD34+DR+ cells were BCR/ABL(-) after 28 days. These results indicate that the CD34+DR- subpopulation of CML marrow still contains leukemic progenitor cells, although to a lesser extent than either LDBM or CD34+DR+ cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679000

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

Review 1.  Autografting as first line treatment for chronic myeloid leukaemia.

Authors:  I O Singer; I M Franklin
Journal:  J Clin Pathol       Date:  1998-02       Impact factor: 3.411

Review 2.  Benign hematopoietic progenitors in chronic myeloid leukemia: current status and future prospects.

Authors:  F Cervantes; C Rozman
Journal:  Ann Hematol       Date:  1994-09       Impact factor: 3.673

3.  The majority of T lymphocytes are polyclonal during the chronic phase of chronic myelogenous leukemia.

Authors:  N Tsukamoto; M Karasawa; T Maehara; K Okamoto; H Sakai; T Naruse; K Morita; J Tsuchiya; M Omine
Journal:  Ann Hematol       Date:  1996-02       Impact factor: 3.673

4.  Persistence of bcr-abl mRNA-expressing cells in long-term cultures established from chronic myeloid leukemic bone marrow or blood.

Authors:  G Pasternak; L Pasternak
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.